Patents by Inventor Andressa Smith

Andressa Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Co-Therapy Comprising A Small Molecule CSF-1R Inhibitor And An Agonistic Antibody That Specifically Binds CD40 For The Treatment Of Cancer
    Publication number: 20210093719
    Abstract: The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 1, 2021
    Inventors: Michael Quigley, Andressa Smith
  • Co-therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer
    Patent number: 10857230
    Abstract: The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Quigley, Andressa Smith
  • Agonistic antibodies specifically binding CD40 and methods of use
    Patent number: 10544229
    Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 28, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Paul Kim, Michael Quigley, Andressa Smith, Alexey Teplyakov, Hong Zhou
  • CO-THERAPY COMPRISING A SMALL MOLECULE CSF-1R INHIBITOR AND AN AGONISTIC ANTIBODY THAT SPECIFICALLY BINDS CD40 FOR THE TREATMENT OF CANCER
    Publication number: 20180250398
    Abstract: The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 6, 2018
    Inventors: Michael QUIGLEY, Andressa Smith
  • Agonistic Antibodies Specifically Binding CD40 and Methods of Use
    Publication number: 20170088624
    Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: September 30, 2016
    Publication date: March 30, 2017
    Inventors: Johan Fransson, Paul Kim, Michael Quigley, Andressa Smith, Alexey Teplyakov, Hong Zhou